echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The world's first drug to treat Smith-Magillian syndrome has been approved

    The world's first drug to treat Smith-Magillian syndrome has been approved

    • Last Update: 2021-01-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Hetlioz is a group of melatonin-affected exciters, melatonin is one of the hormones secreted by the brain pineal gland, secretion has a distinct circadian rhythm, day secretion is inhibited, night secretion is active, has the effect of improving sleep.
    Hetlioz improved the patient's reversed circadian rhythm by agitated SMS patient melatonin-like.
    the approval was based on a double-blind, placebo-controlled cross-clinical study of SMS patients (NCT 02231008), in which subjects were given Hetlioz (1h before bed) and placebo treatment for 4 weeks, stopped for 1 week, and then cross-drug.
    efficacy was compared to the end point of sleep quality score and sleep length.
    results showed that 50 percent of patients in the Hetlioz group had significant statistical differences in the average quality score for the nights with the worst sleep quality compared to the placebo group.
    50% of the total sleep duration at night was better than that of the placebo group, but there was no significant difference.
    -Magill syndrome (SMS) is a rare non-hereditary neurodevelopmental disorder caused by a small loss of 17p chromosomes.
    most common symptoms are sleep disorders, which have reversed circadian rhythms and difficulty falling asleep at night, severely affecting the lives of patients and their families.
    estimates that about one in every 15,000-25,000 children in the United States suffers from the disease. Dr. Mihael H. Polymeropoulos, President of
    Vanda, said, "Thanks to the cooperation of SMS patients and their families, as well as the researchers and staff involved in the design and implementation of this research program, their efforts have enabled Hetlioz to be approved by the FDA, and we remain committed to providing treatment for people with SMS sleep disorders."
    "
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.